GeoVax to Participate in BIO International Convention 2025
ATLANTA, GA - June 12, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO International Convention being held June 16-19, 2025 at the Boston Convention and Exhibition Center in Boston, Massachusetts.
The BIO International Convention is the world's largest gathering of the biotechnology industry, attracting thousands of biotechnology and pharmaceutical executives from around the globe. The event provides an ideal venue for companies to engage with potential partners, investors, and policymakers.
During the convention, GeoVax will participate in business development and partnering meetings to discuss its expanding pipeline of infectious disease and cancer immunotherapies, including GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting Mpox and smallpox; GEO-CM04S1, a multi-antigen COVID-19 vaccine candidate; and Gedeptin(R), a gene-directed enzyme prodrug therapy for the treatment of solid tumors.
GeoVax's participation at BIO 2025 supports its broader business development strategy, including ongoing efforts to establish strategic partnerships, expand manufacturing capabilities, and align with public and private sector priorities in pandemic preparedness, oncology, and biodefense.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Company Contact:
[email protected]
678-384-7220
Investor Relations
[email protected]
212-698-8696
Contact: Media Contact:
Jessica Starman
[email protected]
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
12 minutes ago
- Wall Street Journal
Wholesale Inflation Undershot Forecasts in May
Wholesale inflation undershot expectations last month, according to a Labor Department report that came a day after a weaker-than-forecast reading on consumer prices. Producer prices rose 0.1% in May from April, below the 0.2% rise economists polled by The Wall Street Journal had expected. Over the past 12 months, the producer-price index rose 2.6%, slightly above April's revised figure.
Wall Street Journal
16 minutes ago
- Wall Street Journal
RH Swings to Surprise Profit Despite Tariff Pressures
RH swung to a profit in its fiscal first quarter despite the impact of tariffs on spending and the shakiest housing market in decades, pushing its shares higher after hours. The furniture retailer posted a profit of $8 million, or 40 cents a share, for the quarter ended May 3. That stacks against a loss of $3.6 million, or 20 cents a share, in the comparable quarter a year earlier. Analysts polled by FactSet had been expecting another loss.
New York Times
24 minutes ago
- New York Times
Trump Shifts Deportation Focus, Pausing Raids on Farms, Hotels and Eateries
The Trump administration has abruptly shifted the focus of its mass deportation campaign, telling Immigration and Customs Enforcement officials to largely pause raids and arrests in the agricultural industry, hotels and restaurants, according to an internal email and three U.S. officials with knowledge of the guidance. The decision suggested that the scale of President Trump's mass deportation campaign — an issue that is at the heart of his presidency — is hurting industries and constituencies that he does not want to lose. The new guidance comes after protests in Los Angeles against the Trump administration's immigration raids, including at farms and businesses. It also came as Mr. Trump made a rare concession this week that his crackdown was hurting American farmers and hospitality businesses. The guidance was sent on Thursday in an email by a senior ICE official, Tatum King, to regional leaders of the ICE department that generally carries out criminal investigations, including work site operations, known as Homeland Security Investigations. 'Effective today, please hold on all work site enforcement investigations/operations on agriculture (including aquaculture and meat packing plants), restaurants and operating hotels,' he wrote in the message. The email explained that investigations involving 'human trafficking, money laundering, drug smuggling into these industries are OK.' But it said — crucially — that agents were not to make arrests of 'non-criminal collaterals,' a reference to people who are undocumented but who are not known to have committed any other crime. Want all of The Times? Subscribe.
